Endovascular repair of aortic disease: a venture capital perspective

about

How venture capitalists decide which new medical technologies come to exist

P2860

Q58136474-1A5C69A8-98D7-461B-8740-36D9208A577A

P2860

Endovascular repair of aortic disease: a venture capital perspective

Item

http://www.wikidata.org/entity/Q42593240

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Endovascular repair of aortic disease: a venture capital perspective

@en

Endovascular repair of aortic disease: a venture capital perspective

@nl

type

Item

label

Endovascular repair of aortic disease: a venture capital perspective

@en

Endovascular repair of aortic disease: a venture capital perspective

@nl

prefLabel

Endovascular repair of aortic disease: a venture capital perspective

@en

Endovascular repair of aortic disease: a venture capital perspective

@nl

P1476

Endovascular repair of aortic disease: a venture capital perspective

@en

P2093

Jeffrey Solomon

http://www.w3.org/2001/XMLSchema#string

Joshua B Resnick

http://www.w3.org/2001/XMLSchema#string

Lucas W Buchanan

http://www.w3.org/2001/XMLSchema#string

S William Stavropoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis.

Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial.

Endoleak management following endovascular aneurysm repair.

Fenestrated and branched stent grafts.

Barriers to endovascular aortic aneurysm repair: past experience and implications for future device development.

Past, present, and future endograft devices.

Long-term results of endovascular abdominal aortic aneurysm treatment with the first generation of commercially available stent grafts.

Fueling innovation in medical devices (and beyond): venture capital in health care.

Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB.

Market entry and exit by biotech and device companies funded by venture capital.

P304

56-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/S-0029-1208384

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49841156

http://www.w3.org/2001/XMLSchema#string

P698

21326532

http://www.w3.org/2001/XMLSchema#string

P932

3036456

http://www.w3.org/2001/XMLSchema#string

Endovascular repair of aortic disease: a venture capital perspective

about

P2860

P2860

Endovascular repair of aortic disease: a venture capital perspective

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932